Pirtobrutinib is currently approved for the treatment of patients with CLL/SLL who have received at least 2 prior lines of therapy.
AstraZeneca ((AZN)), Abbvie ((ABBV)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert ...
MedPage Today on MSN
New Combination and Single-Agent Therapies for CLL
Combination Therapies. Zanubrutinib Plus Venetoclax. Fixed-duration therapies with Bruton's tyrosine kinase (BTK) inhibitors and BCL2 inhibitors are emerging as a new treatment op ...
Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global, commercial ...
In the Phase 3 BRUIN CLL-313 study, treatment with pirtobrutinib demonstrated a highly statistically significant and clinically meaningful improvement in progression-free survival versus bendamustine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback